211 related articles for article (PubMed ID: 37999621)
1. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life.
Pugliese N; Polverini D; Arcari I; De Nicola S; Colapietro F; Masetti C; Ormas M; Ceriani R; Lleo A; Aghemo A
Trop Med Infect Dis; 2023 Nov; 8(11):. PubMed ID: 37999621
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
3. Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.
Fabrizi F; Tripodi F; Cerutti R; Nardelli L; Alfieri CM; Donato MF; Castellano G
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423179
[TBL] [Abstract][Full Text] [Related]
4. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Ruiz-Cobo JC; Llaneras J; Forns X; Gallego Moya A; Conde Amiel I; Arencibia A; Diago M; García-Samaniego J; Castellote J; Llerena S; Rodríguez-Seguel E; Mateos B; Rodríguez M; Rosales Zabal JM; Fernández I; Calleja JL; Morillas RM; Montoliu S; Andrade RJ; Badia Aranda E; Hernández-Guerra M; Maté CJ; González-Santiago JM; de Cuenca B; Bernal-Monterde V; Delgado M; Turnes J; Lens S; Buti M
Aliment Pharmacol Ther; 2024 May; ():. PubMed ID: 38695095
[TBL] [Abstract][Full Text] [Related]
5. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
6. Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Ding YJ; Lu CK; Chen WM; Tung SY; Wei KL; Shen CH; Hsieh YY; Yen CW; Chang KC; Chiu WN; Hung CH; Lu SN; Chang TS
J Gastroenterol Hepatol; 2021 Oct; 36(10):2911-2916. PubMed ID: 33978973
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.
Liu CH; Peng CY; Liu CJ; Chen CY; Lo CC; Tseng KC; Su PY; Kao WY; Tsai MC; Tung HD; Cheng HT; Lee FJ; Huang CS; Huang KJ; Shih YL; Yang SS; Wu JH; Lai HC; Fang YJ; Chen PY; Hwang JJ; Tseng CW; Su WW; Chang CC; Lee PL; Chen JJ; Chang CY; Hsieh TY; Chang CH; Huang YJ; Kao JH
Hepatol Int; 2023 Apr; 17(2):291-302. PubMed ID: 36701081
[TBL] [Abstract][Full Text] [Related]
8. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
[TBL] [Abstract][Full Text] [Related]
9. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
Dietz J; Di Maio VC; de Salazar A; Merino D; Vermehren J; Paolucci S; Kremer AE; Lara M; Pardo MR; Zoller H; Degasperi E; Peiffer KH; Sighinolfi L; Téllez F; Graf C; Ghisetti V; Schreiber J; Fernández-Fuertes E; Boglione L; Muñoz-Medina L; Stauber R; Gennari W; Figueruela B; Santos J; Lampertico P; Zeuzem S; Ceccherini-Silberstein F; García F; Sarrazin C; ; ;
J Hepatol; 2021 Apr; 74(4):801-810. PubMed ID: 33220331
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States.
Gordon S; Lee J; Smith N; Dieterich D
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):251-257. PubMed ID: 31204882
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
13. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.
Zhuang L; Li J; Zhang Y; Ji S; Li Y; Zhao Y; Li B; Li W; Quan M; Duan Y; Zhao H; Cheng D; Wang X; Ou W; Xing H
Ann Hepatol; 2021; 23():100268. PubMed ID: 33059055
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis.
Xie J; Xu B; Wei L; Huang C; Liu W
Infect Dis Ther; 2022 Aug; 11(4):1661-1682. PubMed ID: 35749010
[TBL] [Abstract][Full Text] [Related]
16. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy.
Gheorghe L; Preda C; Trifan A; Manuc M; Stanciu C; Istratescu D; Popescu CP; Diculescu MM; Tieranu CG; Manuc T; Stroie TG; Iacob SM; Iliescu L
J Gastrointestin Liver Dis; 2022 Dec; 31(4):437-443. PubMed ID: 36535062
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
Belperio PS; Shahoumian TA; Loomis TP; Backus LI
J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
[TBL] [Abstract][Full Text] [Related]
18. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar Experience.
Bwa AH; Nangia G; Win STS; Maung ST; Han KAW; Htar SS; Wine LY; Ko WW; Oo MP; Hlaing NKT; Palecki J; Loza BL; Win KM; Reddy R
J Clin Exp Hepatol; 2019; 9(3):283-293. PubMed ID: 31360020
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.
Curry MP; Flamm SL; Milligan S; Tsai N; Wick N; Younossi Z; Afdhal NH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1239-1248. PubMed ID: 34105360
[No Abstract] [Full Text] [Related]
20. Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug-Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA).
Fagiuoli S; Toniutto P; Coppola N; Ancona DD; Andretta M; Bartolini F; Ferrante F; Lupi A; Palcic S; Rizzi FV; Re D; Alvarez Nieto G; Hernandez C; Frigerio F; Perrone V; Degli Esposti L; Mangia A
Ther Clin Risk Manag; 2023; 19():57-65. PubMed ID: 36699017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
